RxDoctor Payments Data

Pratima Patil, NP

Family · Hamden, CTNPI 1881141802

Payments from drug & device makers

$1,840in general payments, 2019–2025

Across 58 payments — averaging $31.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$867
  • Astellas Pharma US Inc$278
  • GSK$188
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$114
  • Pfizer$97
  • Novo Nordisk$86
  • plus $210 from 7 others

What the payments were for

  • Food & beverage$1,78097%
  • Education$603%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,840 in reported general payments places this provider in the 80th percentile of 1,596 family providers in Connecticut.

See all family providers in Connecticut

Medicare billing

Part B allowed, 2024
$63,099
Medicare patients
162
Services billed
704

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban132$83,927
JardianceEmpagliflozin56$34,972
OzempicSemaglutide30$28,687
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$22,785
MounjaroTirzepatide17$20,263
FarxigaDapagliflozin Propanediol33$20,198
JanuviaSitagliptin Phosphate18$10,719
XareltoRivaroxaban14$8,481
LinzessLinaclotide11$6,649
Dexlansoprazole DrDexlansoprazole15$3,257
Atorvastatin Calcium276$3,016
Potassium Chloride70$3,010
Rosuvastatin Calcium143$2,464
Travoprost17$2,344
ShingrixVaricella-Zoster Ge/As01b/Pf11$2,307

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$97$83,927132 claims
Boehringer IngelheimJardiance$25$34,97256 claims
Novo NordiskOzempic$86$28,68730 claims
GSKTrelegy Ellipta, Shingrix$188$25,09147 claims
AstraZenecaFarxiga$867$20,19833 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,596 family providers in Connecticut.

Other family in Hamden

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →